[Marketing of the LIFE trial anticipates evaluation of the drug].
Järhult
Bengt
B
bengt.jarhult@ltkronoberg.se
D000329:Advertising / Q000331:legislation & jurisprudence; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use*; D001262:Atenolol / Q000191:economics / Q000627:therapeutic use; D016265:Conflict of Interest; D004345:Drug Industry / Q000592:standards*; D004992:Ethics, Medical; D006801:Humans; D019808:Losartan / Q000191:economics / Q000627:therapeutic use*; D008389:Marketing of Health Services / Q000331:legislation & jurisprudence / Q000592:standards*; D016032:Randomized Controlled Trials as Topic; D013548:Sweden
D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan
Marknadsföringen av LIFE-studien föregriper värderingen av läkemedlet.